Progestins and recurrence in breast cancer survivors

Journal of the National Cancer Institute

Volumn 97, Issue 7, 2005, Pages 471-472

  Chlebowski, Rowan T ^a   Anderson, Garnet L ^b  

^a UCLA MEDICAL CENTER   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; ESTRADIOL; ESTROGEN; GESTAGEN; LUBRICATING AGENT; MEDROXYPROGESTERONE ACETATE; PAROXETINE; TAMOXIFEN; TIBOLONE; VENLAFAXINE; PREGNANE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CLINICAL TRIAL; DATA ANALYSIS; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG USE; FEMALE; HORMONAL THERAPY; HUMAN; HYSTERECTOMY; MENOPAUSAL SYNDROME; PRIORITY JOURNAL; RECURRENCE RISK; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; VAGINA DISEASE; VASOMOTOR DISORDER; VULVA DISEASE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; ESTROGEN THERAPY; EUROPE; HOT FLUSH; MENOPAUSE; METHODOLOGY; NOTE; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SURVIVOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

BREAST NEOPLASMS; ESTROGEN RECEPTOR MODULATORS; ESTROGEN REPLACEMENT THERAPY; EUROPE; FEMALE; HOT FLASHES; HUMANS; MENOPAUSE; NEOPLASM RECURRENCE, LOCAL; NORPREGNENES; PROGESTINS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; RISK FACTORS; SURVIVORS; TREATMENT OUTCOME;

EID: 15944419158     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/dji100     Document Type: Article

References (19)

1. Holmberg L, Anderson G. HABITS (hormonal replacement therapy after breast cancer - is it safe?), a randomized comparison stopped. Lancet 2004;363:453-5.
2. Von Schoultz E, Rutqvist LE. Menopausal hormone therapy after breast cancer: the Stockholm Randomized Trial. J Natl Cancer Inst 2005;97:533-5.
3. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12.
4. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002;288:321-33.
5. Chlebowski RT, Kim JA, Col NF. Estrogen deficiency symptom management in breast cancer survivors in the changing context of menopausal hormone therapy. Semin Oncol 2003;30:776-88.
6. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, et al. American Society of Clinical Oncology Assessment on the use of aromatase inhibitors as adjuvant therapy of postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005;23:1-11.
7. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiologic studies of 30 countries, including 50302 women with breast cancer and 96973 women without disease. Lancet 2002;360:187-95.
8. Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-16.
9. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, et al. Influence of estrogen plus progestin on breast cancer mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-53.
10. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27.
11. Colditz GA. Estrogen, estrogen plus progestin therapy, and risk of breast cancer. Clin Cancer Res 2005;11:909s-17s.
12. Kerlikowske K, Miglioretti DL, Ballard-Barbash R, Weaver DL, Buist DS, Barlow WE, et al. Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. J Clin Oncol 2003;21:4314-21.
13. O'Meara ES, Rossing MA, Daling JR, Elmore JG, Barlow WE, Weiss NS. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 2001;93:754-62.
14. Kim JA, Chlebowski RT, Col NF. Hormone replacement therapy's effects on recurrence and mortality among breast cancer survivors. Med Decis Making 2002;22:532.
15. Naessen T, Rodriguez-Macias K. Serum lipid profile improved by ultra-low doses of l7beta-estradiol in elderly women. J Clin Endocrinol Metab 2001;86:2757-62.
16. Barton D, Loprinzi CL. Making sense of the evidence regarding nonhormonal treatment for hot flashes. Clin J Oncol Nurs 2004;8:39-42.
17. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003;95:1758-64.
18. Liu B, Edgerton S, Yang X, Kim A, Ordonez-Erean D, Mason T, et al. Low-dose dietary phytoestrogen abrogates tamoxifen-associated mammary tumor prevention. Cancer Res 2005;65:879-86.
19. Kroiss R, Fentiman IS, Helmond FA, Rymer J, Foidart JM, Bundred N, et al. The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial. Br J Obstet Gynecol 2005;112:228-33.